Basilea Pharmaceutica (BSLN) investor relations material

2026 financial guidance

• FY 2026 Cresemba- and Zevtera-related revenue raised to ~CHF 250 million from ~CHF 210 million; FY 2025 actual was CHF 194.4 million.

• FY 2026 total revenue expected at ~CHF 310 million, up ~33% YoY; R&D expenses expected at ~CHF 125 million, up ~18% YoY.

• FY 2026 operating profit guidance raised to ~CHF 115 million from CHF 70 million; FY 2025 actual was CHF 51.5 million, with the updated outlook representing ~123% YoY growth.

• Cresemba- and Zevtera-related cash contribution now expected at ~CHF 215 million versus ~CHF 180 million previously; milestone payments expected at ~CHF 65 million versus ~CHF 35 million.

Agenda 2030 strategy

• Cumulative 2026–2030 cash flow target from Cresemba and Zevtera increased to CHF 650 million from CHF 600 million.

• By 2030, the ambition is a diversified business with four commercialized products and an industry-leading anti-infectives R&D pipeline.

Late-stage clinical programs

• Ceftibuten-ledaborbactam development planned as one Phase 2/3 study umbrella, without a separate confirmatory Phase 3; fewer patients are expected than in two separate Phase 3 studies.

• Ceftibuten-ledaborbactam Phase 2/3 study remains on track to start mid-2027; Phase 2 data readout could come as early as end-2028, targeting broad, unrestricted use for complicated UTIs.

• Fosmanogepix global Phase 3 readouts are targeted for mid-2028; recruitment is complete in the invasive mold infection salvage cohort and continues in other mold cohorts and invasive candidiasis.

• Initial fosmanogepix regulatory filings are planned to include results from both Phase 3 studies, supporting the goal of pursuing the broadest possible launch label.